VANCOUVER, BC / ACCESS Newswire / January 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusively-licensed technology, a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the "Technology"), which was shown in a study1 to successfully prevent the regeneration of cancer cells, by disrupting DNA repair processes, making cancer cells more vulnerable to radiation therapy and thereby improving patient outcomes.
Onco-Innovations' new generation of PNKP inhibitors targets a key enzyme involved in cancer cell DNA repair. By inhibiting PNKP, these compounds can prevent cancer cells from repairing damage caused by radiation therapy, significantly boosting the therapy's effectiveness. This innovative approach can not only improve treatment outcomes by reducing the chances of cancer recurrence but also offers the potential for longer-term remission and improved patient survival rates.
Cancer recurrence remains a significant challenge in oncology, with varying rates depending on the type of cancer. For instance, colon cancer recurs in approximately 30% to 40% of patients who have completed treatment, including surgery and chemotherapy2, with most recurrences happening within the first two to three years and about 95% of recurrences happen within 4 years of surgery3. Similarly, epithelial ovarian cancer has a strikingly high recurrence rate of 85%4, while bladder cancer, even after the surgical removal of the bladder, shows a local recurrence rate of 30% to 54%5. These statistics underscore the critical need for advanced therapies that not only treat the initial cancer but also effectively reduce the risk of recurrence, thereby improving long-term patient outcomes.
Reducing cancer recurrence improves patient survival and cuts healthcare costs by limiting the need for further treatments. Onco-Innovations' Technology, by showing the potential to prevent cancer cell regeneration, offers a promising potential solution that could enhance outcomes while potentially saving millions in healthcare expenses.
"Addressing the critical challenge of cancer cell regeneration, our Technology represents a major leap forward in oncology. By potentially disrupting this fundamental process, we can enhance the effectiveness of treatments and reduce the risk of recurrence. This Technology not only carries the potential to improve patient outcomes but could also offer significant potential for cost savings within the healthcare system," said Thomas O'Shaughnessy, CEO of the Company.
1 Front. Oncol., 22 December 2021 Sec. Cancer Molecular Targets and Therapeutics Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.772920
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868559/
3 https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02207-4
4 https://www.tandfonline.com/doi/abs/10.1080/14737140.2017.1398088?journalCode=iery20&
5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799348/
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented groundbreaking technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel:+ 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Technology, the Company's ability to submit and complete U.S. FDA trials, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Technology, the failure to complete U.S. FDA clinical trials, the failure to receive regulatory approval in respect of the Technology, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
